Follow The Filings

CRSP Crispr Therapeutics AG

Health Care, filed as CRISPR THERAPEUTICS AG (NAMEN AKT), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 3 Owners
  • Max 3.4%
  • $519M
  • 1 reduce 1 small

In 2026 Q2 Cathie Wood trimmed Crispr Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 3.4% (Cathie Wood, Ark Investment Management). Not free-float ownership.

  1. Cathie Wood Reduce 3.4%
  2. Palo Alto Investors 0.30%
  3. Murray Stahl Reduce 0.01%

Who owns CRSP

Sorted by value, long equity only, as of 2026 Q2.

History
Cathie Wood, Ark Investment Management 3.4%, was 4.2% Reduce −16.4% 9,460,939 $516M History
Palo Alto Investors 0.30% Hold 39,605 $2.2M History
Murray Stahl, Horizon Kinetics Asset Management 0.01% Small trim −4.5% 9,353 $510K History

3 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by CRSP's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CRSP insider trades
  • None no insider bought on the open market
  • $781K sold by 1 insider outside a trading plan
  • $11.1M sold by 4 insiders under 10b5-1 plans
  1. Simeon George Director
    Planned sale
    $720K 14,514 shares at $49.63 48% of stake
    Traded Oct 14 Filed Oct 16
    ↗
  2. James R. Kasinger General Counsel and Secretary
    Planned sale
    $119K 1,990 shares at $60.04 2.1% of stake
    Traded Oct 6 Filed Oct 8
    ↗
  3. James R. Kasinger General Counsel and Secretary
    Planned sale
    $626K 10,400 shares at $60.24 9.9% of stake
    Traded Sep 22 Filed Sep 24
    ↗
  4. Ali Behbahani Director
    Sale
    $781K 13,679 shares at $57.09 45% of stake
    Traded Sep 17 Filed Sep 21
    ↗
  5. Naimish Patel Chief Medical Officer
    Buy
    $50K 1,508 shares at $32.96 New stake
    Traded Apr 3, 2025 Filed Jan 27
    ↗
  6. Raju Prasad CFO
    Planned sale
    $2.1M 34,972 shares at $60.19 84% of stake
    Traded Jan 22 Filed Jan 26
    ↗
  7. Samarth Kulkarni CEO
    Planned sale
    $5.2M 90,000 shares at $57.40 40% of stake
    Traded Jan 20–22 Filed Jan 22
    ↗
  8. Raju Prasad CFO
    Planned sale
    $1.8M 29,700 shares at $60.16 81% of stake
    Traded Jan 6 Filed Jan 8
    ↗
  9. Raju Prasad CFO
    Planned sale
    $560K 10,000 shares at $55.95 60% of stake
    Traded Dec 22, 2025 Filed Dec 23, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 23 option exercises, 16 sales to cover taxes, and 3 gifts.

Congress

No member of Congress reported trading CRSP in the last three years. 1 member listed it in 2025 annual reports.

All Congress trades

SEC filings

Recent issuer filings from EDGAR, 12 shown.

Filed Form Detail Links
8-K 5.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02,5.03,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 3 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $371.21M $37.31M $3.51M
Net income -$153.61M -$366.25M -$581.6M
Net margin * -41.4% -981.5% -16569.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.91B $1.94B $1.99B
Total non-current assets * $321.49M $304.9M $279.57M
Total assets $2.23B $2.24B $2.27B
Total current liabilities $108.79M $87.78M $149.12M
Total non-current liabilities * $237.98M $222.17M $194.31M
Total equity $1.88B $1.93B $1.92B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$260.38M -$142.77M -$345.01M
Cash from investing $374.65M -$280.48M -$31.8M
Cash from financing $62.66M $331.98M $426.03M
Net change in cash $177.01M -$91.29M $49.3M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.